Delay to Australia and European Union mutual recognition
This article was originally published in Clinica
The March election of a new government in Australia has made it difficult to predict when the proposed medical device mutual recognition agreement between Australia and the European Union will be implemented. The MRA was due to come into force on January 1st this year (see Clinica No 676, p 7). Agreement has now been reached on the technical content and the way is clear for the MRA to proceed, reports the Australian Therapeutic Device Bulletin. Officials are scheduled to meet in Brussels during May to initial the agreement. A number of changes to Australia's Therapeutic Goods Act will be required before the MRA can finally be implemented.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.